Albany, NY -- (SBWIRE) -- 04/28/2014 -- A survey conducted by Huidian Research shows that China’s insulin market scale approximately registered CNY 11 billion in 2013, of which CNY 7.5 billion achieved in second-generation insulin market and CNY 3.5 billion generated in third-generation insulin market. Now third-generation insulin market grows faster than second-generation insulin. And second-generation insulin market will accelerate growing space because it is just listed into new essential drug catalogue.
View Full Report with TOC at: http://www.researchmoz.us/research-and-forecast-on-china-insulin-market-2014-2018-report.html
Currently there are only two companies owning full series of insulin products globally, Tonghua Dongbao is one of the two. As for global insulin market at present, only three companies, including Tonghua Dongbao, Novo Nordisk and Eli Lilly, produce second-generation insulin in quantity. Under oligopolistic competition in the global market, it is difficult to tell which companies’ products are better, but Tonghua Dongbao enjoys the lowest overall production cost. Compared with expensive insulin produced by transnational giants, governments can reduce expenditure of health insurance if buying Dongbao’s insulin, so Tonghua Dongbao will become a powerful contender when competing for more market shares with transnational giants in the developing countries.
Four domestic companies obtained production approval of second-generation insulin, namely United Laboratories, Donghua Tongbao, Wanbang and Shenzhen Kexing Biotech. The latter two received production approval in 2003, but their products did not sell in market due to bad quality. Currently Wanbang’s animal insulin injections enjoy the largest sales volume in China.
Third-generation insulin in foreign market covers rapid-acting insulin (insulin aspart and insulin lispro) and long-acting insulin (insulin glargine and insulin detemir). Recombinant insulin lispro and its injection, which are high-end products, also belong to third-generation insulin. Third-generation insulin is quicker to take effects and also can better simulate physiologic insulin secretion pattern. Information disclosed by China Food and Drug Administration show that Eli Lilly and Company and Gan & Lee (a private company in China) owns production approval documents of this type of insulin. Affected by its commercial bribery case, business performance of Gan & Lee witnessed a significant drop in 2013, but its third-generation insulin that is a foreign-funded brand with dominant position in market had not been influenced much.
Browse More Reports Pharmaceutical: http://www.researchmoz.us/pharmaceutical-market-reports-38.html
Research holds a view that for now third-generation insulin is superior in effects but its price is far higher than second-generation insulin, low and middle income patients without medical insurance are hard to pay for the expensive drug cost. So in wide grass roots market, second-generation insulin enjoys an overwhelming superiority. But it is predicated that with the decreasing price, third-generation insulin will replace second-generation insulin in the next years, representing the general trend.
Partnerships, Licensing, Investments and M&A Deals and Trends for February 2014 in Pharmaceuticals
The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in February 2014. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Browse Full Report with TOC at: http://www.researchmoz.us/partnerships-licensing-investments-and-manda-deals-and-trends-for-february-2014-in-pharmaceuticals-report.html
Global and China Printed sets of drugs Industry 2014 Market Research Report
The report firstly introduced Printed sets of drugs basic information included Printed sets of drugs definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, Printed sets of drugs industry policy and plan, Printed sets of drugs product specification, manufacturing process, product cost structure etc. Browse Full Report with TOC at: http://www.researchmoz.us/global-and-china-printed-sets-of-drugs-industry-2014-market-research-report-report.html
ResearchMoz ( http://www.researchmoz.us/ ) is the one stop online destination to find and buy market research reports. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. We provide the market context, competitor insight and future trends needed for strategic planning.
For More Information Kindly Contact:
Toll Free: 866-997-4948